| Richard Mcmullan, NP | |
|
15190 Community Rd Ste 260, Gulfport, MS 39503-3471 | |
| (228) 575-8020 | |
| Not Available |
| Full Name | Richard Mcmullan |
|---|---|
| Gender | Male |
| Speciality | Clinical Nurse Specialist - Acute Care |
| Location | 15190 Community Rd Ste 260, Gulfport, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033973359 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2100X | Clinical Nurse Specialist - Acute Care | 906506 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Richard Mcmullan, NP 3704 Bienville Blvd Ste B, Ocean Springs, MS 39564-5710 Ph: (228) 872-4040 | Richard Mcmullan, NP 15190 Community Rd Ste 260, Gulfport, MS 39503-3471 Ph: (228) 575-8020 |
News Archive
PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that pursuant to the Federal Acquisition Regulations and pending a ruling in a protest recently filed by a competitor the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), has suspended work under the modification the Company announced on February 23, 2010 to its existing contract with BARDA for the research and development of SparVax™. June 11, 2010 is the deadline to rule on the protest.
Programmed cell death is an integral part of embryonic development. Exploring the regulation of the process, Ludwig-Maximilians-Universitaet in Munich researchers have shown that so-called microRNAs protect the precursors of neurons from 'precocious' elimination.
New research from Boston Medical Center shows that routine Hepatitis C (HCV) testing at federally qualified health centers improves diagnosis rates and health outcomes for people with HCV infections in the United States, and is cost-effective.
Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen.
Dr. Lisa Weinstock, Director of Women's Digital Imaging in Ridgewood, said she has added Hologic Low-Dose 3-D Mammography (Breast Tomosynthesis) with C-View 2-D Imaging to enhance breast cancer screening of patients.
› Verified 9 days ago
Mrs. Susan Knowlton, FPMHNP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1600 Broad Ave, Gulfport, MS 39501 Phone: 228-863-1132 Fax: 228-865-1700 |